Benefit from the most complete clinical trial and drug landscape for immune checkpoint modulators
What we cover
Beacon Checkpoint is a sector-specific curated database that includes trial and drug records for preclinical, active, approved, and discontinued:
- Immune Checkpoint Modulator Combinations
- Immune Checkpoint Modulators Monotherapies
- Across over 27 different checkpoint targets
New data expansion: Deals and Companies. Gain unparalleled access to in-depth company profiles and the latest commercial deals. Monitor your competitors and opportunities as well as benchmark deals and evaluate potential partners. Learn more about Deals and Companies data by downloading the factsheet.
How Beacon helps
Here are a few example use cases that have benefitted our clients in accelerating their checkpoint development programs:
- Benchmark drug development and clinical trial strategies against competitors.
- Get an in-depth overview of the landscape and insights into your competitors’ preclinical and clinical assets.
- Drastically reduce manual research time with our database solution which allows users to rapidly assemble data for analysis on, line of therapy, clinical trial arms, disease indication, and much more.
- Identify new players and new assets entering the clinic and monitor their progress.
- Real time updates to help you keep abreast of new players, clinical entries and data releases.
How Beacon Checkpoint works
Our intelligent search function instantly sweeps the clinical trial and drug landscape using 20 search criteria including therapeutic class, target, disease indication, developer, drug status and more. Search for combinations in trials or individual arms to avoid false positives.
The unique Milestones filter and visualization highlights past, present, and future drug development milestones including drug and trial readouts, asset history, and regulatory announcements. This enhancement provides an accurate, timely and exhaustive single-drug timeline allowing you to benchmark progress in the checkpoint space.
If publicly available, information regarding trials where an immune checkpoint is in combination with an antibody-drug conjugate, bispecific, cell therapy or gene therapy will also be included in our trial coverage.
How we source the data for checkpoint therapies
We house all publicly available sources of data updated with 24 – 48 hours of publication proactively. Our sources cover (but are not limited to):
- Clinical trials registries
- Scientific journals and publications
- Company reports and presentations
- Press releases
- Conference reports and abstracts
- Government and regulatory organizations
- Newspapers and other media
Our Checkpoint Expert
Zer En Peng is the lead research analyst for checkpoint-based drugs and trials in the Beacon team.
Sign up to his weekly newsletter with the latest checkpoint landscape insights and updates with data from Beacon Checkpoint.
Other Beacon Solutions
Covering all Antibody Drug Conjugates (ADCs), Small Molecule Drug Conjugates (SMDCs), Protein Drug Conjugates (PDCs), Immunotoxins and more
Covering all Bi- and Multi-Specific Antibodies, Antibody Fragments, Augmented Antibodies and more
Beacon Cancer Vaccine provides the solution you need to master the prophylactic and therapeutic cancer vaccines field.
Beacon Cell Therapy covers genetically and non-genetically engineered allogeneic and autologous cell-based therapies across all disease indications
Covering all cytokines and drugs that target a cytokine or its immediate receptor belonging to the Interleukins, Interferons, Colony-stimulating factors, Transforming growth factor β, Tumour necrosis factor and Chemokines families.
Beacon DDR steps into the field to give drug developers the precise detailed view and broader picture of what is truly happening in the DDR field.
From gene-editing technologies, novel delivery systems, and a variety of genetic materials being used- Beacon Gene Therapy steps into the field to give drug developers a precise and detailed view of how the gene therapy landscape looks.
Covering all therapeutics aimed at treating immune-mediated diseases – Beacon Immune Tolerance provides drug developers with detailed views of the expanding immune tolerance landscape.
Covering all pharmaceutical grade microbiome-based therapeutics across all disease indications – Beacon Microbiome provides drug developers with detailed views of the expanding microbiome landscape.
From capturing viral family and strains to understanding any genetic modifications – Beacon Oncolytic Viruses steps into the field to give drug developers the precise detailed view and broader picture of what is truly happening in the Oncolytic Virus field.
Covering Oligonucleotide-based, mRNA-Based, Ribozyme, and gRNA-Mediated Gene Editing therapies, as well as RNA-Targeted Small Molecules – Beacon RNA covers all disease indications and many modalities to provide a detailed landscape of the RNA space.
Beacon TPD provides the solution you need to master the targeted protein degradation field.
Any questions? Contact us
To learn more about how we can tailor Beacon Checkpoint to help you, get in touch with our sales team
Priya Soneji & Thomas Vickers
Checkpoint Account Managers
We are a clinical trial and pipeline database solution, designed in partnership with pharmaceutical professionals. We track targeted therapies to provide accurate, in-depth and real-time information in the rapidly evolving landscape of drug development.